CBFB and leukemia: For example, the small molecule inhibitor AI-10-49 selectively disrupted the interaction between the aberrant activator CBF-β and DNA binding transcriptional factor RUNX1, thereby restoring normal expression patterns and delaying leukemia progression in mice [67].